Skip to main content

NEW YORK (TheStreet) -- Intersect ENT (XENT) shares are climbing 2.5% to $25.79 in trading on Wednesday after the commercial stage drug device company upsized its secondary offering by 582,000 shares to 3.582 million shares.

The company priced its offering at $25 per share, a slight decrease from yesterday's closing price of $25.16, resulting in aggregate proceeds of $89.6 million.

J.P. Morgan (JPM) and Bank of America/Merrill Lynch (BAC) are acting as joint book-running managers for the offering.

Image placeholder title


data by